XBiotech

(NASDAQ) XBIT

Current Price$2.27

Market Cap$69.21M

Since IPO (2015)-88%

5 Year-86%

1 Year-24%

1 Month-4%

XBiotech last closing stock price
Metric	Price	Date
Last close	USD 2.27	2026-07-17

XBiotech stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-0.87%	USD 2.29	2026-07-10
1 month	-4.22%	USD 2.37	2026-06-17
3 month	-7.72%	USD 2.46	2026-04-17
Year to date	-5.02%	USD 2.39	2025-12-31
1 year	-24.33%	USD 3.00	2025-07-17
3 year	-57.25%	USD 5.31	2023-07-18
5 year	-86.1%	USD 16.33	2021-07-16
Since inception	-88.42%	USD 19.61	2015-04-16

XBiotech Financials at a Glance

Market Cap

$69.21M

Revenue (TTM)

$0.00

Net Income (TTM)

-$40.16M

EPS (TTM)

-$1.32

P/E Ratio

-1.72

Dividend

$0.00

Beta (Volatility)

1.03 (Average)

Dividend

$0.00

Beta (Volatility)

1.03 (Average)

Price

$2.27

Volume

799

Open

$2.27

Price

$2.27

Volume

799

Open

$2.27

Previous Close

$2.27

Daily Range

$2.26 - $2.27

52-Week Range

$2.09 - $3.61

Estimated Earnings Date

May 12, 2026

Dividend

$0.00

Beta (Volatility)

1.03 (Average)

Price

$2.27

Volume

799

Open

$2.27

Previous Close

$2.27

Daily Range

$2.26 - $2.27

52-Week Range

$2.09 - $3.61

Estimated Earnings Date

May 12, 2026

XBIT News

business person worried GettyImages-474577567

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About XBiotech

XBiotech develops antibody-based drugs for diseases like cancer and COVID-19. Its therapies aim to reduce inflammation and infection in patients. The company’s work targets people with serious health conditions needing new treatment options.

Lab Bench to Bedside: What XBiotech Sells

True Human antibodies: Naturally occurring antibodies from human donors, used to treat inflammation and infection. (0% of revenue in Q2 2025)
Interleukin-1 alpha (IL-1a) therapies: Drugs targeting diseases like cancer, stroke, heart attack, and arthritis. (0% of revenue in Q2 2025)
COVID-19 therapy: Antibody treatment for COVID-19 variants, focused on severe cases. (0% of revenue in Q2 2025)
Pipeline candidates: Early-stage drugs for anti-infective and anti-inflammatory uses. (0% of revenue in Q2 2025)

Growth Moves: XBiotech’s Expansion Playbook

Sold IL-1a antibody asset to Janssen in 2019 for $750 million cash.
Retained rights to develop new IL-1a drugs for non-skin diseases after 2019 sale.
Built new research and development facility in Austin, Texas, completed in early 2025.
No active clinical trials in Q2 2025; focus on preclinical and early-stage research.

Why XBiotech Is a Bit Different

XBiotech uses a unique process to find and clone human antibodies, not animal-based ones. The company keeps all research, development, and manufacturing in-house. It focuses on diseases with few existing treatment options.

Five Things You Need to Know

No product revenue in Q2 2025; all income was $0 for the period.
Net loss was $1.76 million in Q2 2025, improving 86.5% from Q2 2024.
Research and development expenses fell 59% year-over-year in Q2 2025.
Cash and cash equivalents were $152.9 million as of June 30, 2025.
All operations funded by cash reserves; no debt as of June 2025.

Bottom Line

XBiotech remains a research-focused biotech with no commercial products. Its financial health depends on cash reserves and ongoing drug development.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Sushma Shivaswamy, PhD

Website

www.xbiotech.com

Headquarters

Austin, TX 78744, US

XBIT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-26.10%

Return on Capital

-39.68%

Return on Assets

-28.72%

Earnings Yield

-58.14%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$69.21M

Shares Outstanding

30.49M

Volume

799

Avg. Volume

30.44K

Financials (TTM)

Gross Profit

-$332.00K

Operating Income

-$48.41M

EBITDA

-$38.33M

Operating Cash Flow

-$42.17M

Capital Expenditure

-$195.00K

Free Cash Flow

-$42.36M

Cash & ST Invst.

$115.46M

Total Debt

$0.00

XBiotech Performance Analysis

XBiotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 4,010,000	-78.2%
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

XBiotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

XBiotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -1.08	86.5%
2023	2023-12-31	USD -0.81	-25.4%
2024	2024-12-31	USD -1.26	56.8%
2025	2025-12-31	USD -1.49	18.1%

XBiotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	84.0%
Q3	2025-09-30	-247.2%
Q4	2025-12-31	-340.0%
Q1	2026-03-31	79.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$332.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$69.21M

N/A

Market Cap/Employee

$752.25K

N/A

Employees

N/A

Net Income

-$5.51M

+49.4%

EBITDA

-$5.12M

+50.4%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$115.46M

-25.9%

Total Debt

$0.00

N/A

Accounts Receivable

$302.00K

-52.7%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-28.72%

N/A

Return on Invested Capital

-35.38%

N/A

Free Cash Flow

-$8.97M

-31.6%

Operating Cash Flow

-$8.97M

-33.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

GANXGain Therapeutics, Inc.

GANXGain Therapeutics, Inc.$1.71+3.01%

ACETAdicet Bio, Inc.

ACETAdicet Bio, Inc.$8.12-1.22%

TCRXTScan Therapeutics, Inc.

TCRXTScan Therapeutics, Inc.$0.91+1.80%

ACRVAcrivon Therapeutics, Inc. Common Stock

ACRVAcrivon Therapeutics, Inc. Common Stock$1.75+0.00%

NTRBNutriband Inc.

NTRBNutriband Inc.$3.11-0.64%

LITSLite Strategy, Inc.

LITSLite Strategy, Inc.$0.99+1.69%

CRVOCervoMed Inc.

CRVOCervoMed Inc.$3.08-1.91%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$10.12-0.03%

PATHUiPath

PATHUiPath$12.15+0.01%

JOBYJoby Aviation

JOBYJoby Aviation$7.23-0.01%

SOFISoFi Technologies

SOFISoFi Technologies$17.28-0.00%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$67.53-0.05%

HLHecla Mining

HLHecla Mining$14.33-0.01%

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares$27.24-0.01%

Questions About XBIT

What is the current price of XBiotech?

XBiotech is trading at $2.27 per share.

What is the 52-week range for XBiotech?

Over the past 52 weeks, XBiotech has traded between $2.09 and $3.61.

How much debt does XBiotech have?

As of the most recent reporting period, XBiotech reported total debt of $0.00.

How much cash does XBiotech have on hand?

XBiotech reported $115.46M in cash and cash equivalents in its most recent financial results.

What is XBiotech’s dividend yield?

XBiotech does not currently have a dividend yield.

XBiotech

XBiotech Financials at a Glance

XBIT News

Why XBiotech Shares Are Tumbling 23.4% Today

Why XBiotech Shares Are Skyrocketing 32.7% Today

This Small-Cap Biotech Gained as Much as 106.4% Today

These 3 Biotechs Have Been Crushed; Is It Time to Bargain Shop?

Why XBiotech Inc Jumped Higher Today

Why XBiotech Inc. Got Crushed Today

Why XBiotech Inc. Fell 33% Today

Why XBiotech Inc. Made a U-Turn Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About XBiotech

Lab Bench to Bedside: What XBiotech Sells

Growth Moves: XBiotech’s Expansion Playbook

Why XBiotech Is a Bit Different

Five Things You Need to Know

Bottom Line

XBIT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

XBiotech Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About XBIT

What is the current price of XBiotech?

What is the 52-week range for XBiotech?

How much debt does XBiotech have?

How much cash does XBiotech have on hand?

What is XBiotech’s dividend yield?

Premium Investing Services